ZoxazolamineCAS# 61-80-3 |
2D Structure
- Dofequidar
Catalog No.:BCC4176
CAS No.:129716-58-1
- Dofequidar fumarate
Catalog No.:BCC4177
CAS No.:153653-30-6
- LY335979 (Zosuquidar 3HCL)
Catalog No.:BCC3878
CAS No.:167465-36-3
- Tariquidar
Catalog No.:BCC3625
CAS No.:206873-63-4
- Tariquidar methanesulfonate, hydrate
Catalog No.:BCC1986
CAS No.:625375-83-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 61-80-3 | SDF | Download SDF |
PubChem ID | 6103 | Appearance | Powder |
Formula | C7H5ClN2O | M.Wt | 168.58 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (593.19 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 5-chloro-1,3-benzoxazol-2-amine | ||
SMILES | C1=CC2=C(C=C1Cl)N=C(O2)N | ||
Standard InChIKey | YGCODSQDUUUKIV-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C7H5ClN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Zoxazolamine Dilution Calculator
Zoxazolamine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.9319 mL | 29.6595 mL | 59.319 mL | 118.638 mL | 148.2975 mL |
5 mM | 1.1864 mL | 5.9319 mL | 11.8638 mL | 23.7276 mL | 29.6595 mL |
10 mM | 0.5932 mL | 2.966 mL | 5.9319 mL | 11.8638 mL | 14.8298 mL |
50 mM | 0.1186 mL | 0.5932 mL | 1.1864 mL | 2.3728 mL | 2.966 mL |
100 mM | 0.0593 mL | 0.2966 mL | 0.5932 mL | 1.1864 mL | 1.483 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Zoxazolamine is a centrally acting myorelaxant, which is formerly used as an antispasmodic and uricosuric.
- 4-Aminohippuric Acid
Catalog No.:BCC4753
CAS No.:61-78-9
- Phenylephrine HCl
Catalog No.:BCC4335
CAS No.:61-76-7
- Mefenamic Acid
Catalog No.:BCC4433
CAS No.:61-68-7
- Papaverine Hydrochloride
Catalog No.:BCC8348
CAS No.:61-25-6
- Adenosine 5'-monophosphate
Catalog No.:BCC8809
CAS No.:61-19-8
- Dibucaine (Cinchocaine) HCl
Catalog No.:BCC3760
CAS No.:61-12-1
- 2-Methoxycinnamic acid
Catalog No.:BCN5038
CAS No.:6099-03-2
- Geraniin
Catalog No.:BCN2402
CAS No.:60976-49-0
- Bz-Glu-OH
Catalog No.:BCC2922
CAS No.:6094-36-6
- YZ9
Catalog No.:BCC8001
CAS No.:6093-71-6
- 6-Hydroxycoumarin
Catalog No.:BCC9207
CAS No.:6093-68-1
- H-DL-Pro-OH
Catalog No.:BCC3026
CAS No.:609-36-9
- H-Leu-OH
Catalog No.:BCC2968
CAS No.:61-90-5
- Tenuazonic acid
Catalog No.:BCN1859
CAS No.:610-88-8
- Isoacetovanillone
Catalog No.:BCN7166
CAS No.:6100-74-9
- Succinylcholine Chloride Dihydrate
Catalog No.:BCC4564
CAS No.:6101-15-1
- Ferulamide
Catalog No.:BCN4129
CAS No.:61012-31-5
- c-JUN peptide
Catalog No.:BCC8085
CAS No.:610273-01-3
- Teicoplanin
Catalog No.:BCC4731
CAS No.:61036-62-2
- N-Desmethylclozapine
Catalog No.:BCC6887
CAS No.:6104-71-8
- L-Thyroxine sodium salt pentahydrate
Catalog No.:BCC4283
CAS No.:6106-07-6
- Boc-His(Nτ-Me)-OH
Catalog No.:BCC2684
CAS No.:61070-22-2
- Isobonducellin
Catalog No.:BCN4130
CAS No.:610778-85-3
- Icotinib
Catalog No.:BCC4473
CAS No.:610798-31-7
Effects of furazolidone on duration of righting reflex loss induced with hexobarbital and zoxazolamine in the rat.[Pubmed:7999888]
J Vet Med Sci. 1994 Aug;56(4):667-70.
Effects of furazolidone (FZ) on the sleeping time induced with hexobarbital (HEX) and paralysis time induced by Zoxazolamine (ZOX) were investigated by measuring the length of time required to recover from righting reflex loss in rats after oral administration of FZ at doses of 50, 100, 200 and 400 mg/kg/day for 4 successive days. Administration of 50 mg/kg to rats of both sexes induced no effect on the HEX sleeping time, but of 100 mg/kg FZ or more induced prolongation of sleeping time dose-dependently. In female rats, HEX sleeping time of the control group was twice that of the male rats, but HEX sleeping time after receiving FZ above 200 mg/kg was approximately the same as in the male rats. ZOX paralysis time exhibited no sex differences in the control rats, and it was significantly prolonged by FZ at a dose of 100 mg/kg or more. No significant differences in blood levels of HEX and ZOX at the time of recovery were found between the control and FZ treated rats, suggesting that FZ produced prolongation of the drug effects was due to the maintenance of the blood levels rather than the change in the sensitivities of rats at the receptor sites. Body weight gains were inhibited in the rats treated with FZ at doses over 100 mg/kg. Cytochrome P-450 content in hepatic microsomes in the rats which received 100 mg/kg FZ were slightly increased. It is suggested that successive oral administration of FZ to rats at high doses impaired drug clearance and this resulted in the prolongation of HEX sleeping and ZOX paralysis times.
Effects of ciprofloxacin and enrofloxacin on zoxazolamine kinetics, plasma concentration and sleeping times in mice.[Pubmed:8395094]
Toxicol Lett. 1993 Jul;69(1):1-14.
The treatment of CD1 male mice with either ciprofloxacin (CP) or enrofloxacin (EF) prior to Zoxazolamine (ZX) administration increased the mean ZX sleeping times to, respectively, 162 and 156% of the control (ZX alone). At the end of the sleeping time, the mean ZX plasma concentration in controls was 27.2 micrograms/ml and was not different in EF- or CP-treated groups (87% and 95% of controls, respectively). The animals coadministered with CP or EF and ZX eliminated the latter more slowly than the controls. The estimated zero-time drug concentration of the disposition curves of both the CP- and EF-treated groups as well as the apparent half-life of elimination and apparent overall rate of elimination of the CP-treated group were different from the control values.
Zoxazolamine-induced paralysis in two rat substrains: differences in hepatic drug metabolism.[Pubmed:10323328]
Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):461-7.
Aldehyde dehydrogenase (ALDH) is involved in the metabolism of endogenous and exogenous aldehydes originating from biogenic amines, lipids, food and drugs. Rat liver contains at least two cytosolic ALDHs that can be stimulated by inducers of drug metabolism. Phenobarbital- type inducers increase ALDH1 activity while polycyclic aromatic hydrocarbons (such as benzo[alpha]pyrene) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) increase ALDH3c isoenzyme activity. Two rat substrains were isolated according to a different induction of hepatic ALDH after treatment with phenobarbital (PB). Animals that responded to treatment (RR) and those that did not respond (rr) were inbred and divided into two homogenous groups. These animals constituted an ideal experimental model due to their common origin. Apart from the dramatic induction of cytosolic ALDH1 and ALDH3c, the effects of PB on pentoxy-, ethoxy- and methoxy-resorufin-O-dealkylase (P-, E-, and MROD) between the two substrains were also studied. 3-Methylcholanthrene (3MC) greatly increased ALDH3c levels in both substrains, although it was slightly more pronounced in the rr rats, in which it was assessed either as ALDH3c or as total cytosolic ALDH. A similar trend was also noted in EROD, PROD and MROD activities. Dealkylation of the methoxy group was found to be statistically different between the two substrains (rr > RR). The relevance of the biochemical findings with the in vivo hepatic capacity for drug metabolism was investigated by measuring the duration of Zoxazolamine paralysis. Both animal substrains were tested with Zoxazolamine either without pretreatment or after administration of PB or 3MC: the paralysis produced by Zoxazolamine lasted for a longer period in rr than in RR rats. After pretreatment with PB, the duration of paralysis was greatly reduced, but the differences between the two substrains remained. Pretreatment with various doses of 3MC produced differences in the duration of paralysis in RR and rr rats, although the time period was much shorter than that observed in control animals.
Synthesis and characterisation of the first transition metal complex of zoxazolamine (2-amino-5-chlorobenzoxazole): the X-ray crystal structure determination of [ZnCl2(eta 1-Nbenzoxazole-2-amino-5-chlorobenzoxazole)2].[Pubmed:15621301]
J Inorg Biochem. 2005 Feb;99(2):664-7.
The synthesis and characterisation (NMR, X-ray, elemental analysis) of the first transition metal complex of Zoxazolamine (1: 2-amino-5-chlorobenzoxazole), viz. [ZnCl(2)(1)(2)] (2) is described; complex 2 is obtained in 77% yield from the treatment of 1 with ZnCl(2) in acetone solution. The Zn compound is a mononuclear species (X-ray) with a distorted tetrahedral array of ligands around the metal centre with the title ligand bound to Zn via the benzoxazole ring N-atom. The structural properties of 2 are discussed in relation to other mononuclear Zn halide complexes.